Speciality Medicines
Symbol: SPML | Industry: Biotechnology & Drugs
Grey Market Premium (GMP)
GMP ACTIVE+₹0.00
Updated: Recent₹124.00
Based on Max Price: ₹124.00+0.00%
Projections onlyIPO Quick Highlights
IPO Timeline
- IPO Opens 20 Mar 2026
- IPO Closes N/A
- Allotment Date N/A
- Listing Date 30 Mar 2026
About the Company
Speciality Medicines Limited is an India-based pharmaceutical company. The Company is engaged in marketing and distribution of finished formulations of specialty pharmaceuticals. It offers a diverse portfolio of specialty pharmaceuticals, focusing on therapeutic areas such as oncology, immunology, neurology, and rare diseases. It deals in finished formulations of specialty pharmaceuticals, including capsules, cream, eye drops, gel, infusion, inhalation, inhaler, injection, nasal spray, ointment, ophthalmic, oral solution, oral suspension, sachet, suspension and tablet. Its product portfolio consists of more than 900 products, which comprises of wide range of therapeutic drugs such as ACE inhibitors, Analgesic, Antiulcer, Anti angiogenic, Anti-acne, and Anti fibrinolytic, among others. Under the sale of specialty pharmaceutical finished formulation in the domestic market, it sources existing Indian medicine brands from manufacturers and their authorized distributors.
Promoters & Key Management
| Rank | Officer Name | Designation | Age | Since |
|---|---|---|---|---|
| #1 | Parthkumar Babulal Goyani | Executive Chairman of the Board, Managing Director | 35 | 2021 |
| #2 | Kalpesh Bharatbhai Pipaliya | Chief Financial Officer | 30 | 2025 |
| #3 | Anita Kumawat | Compliance Officer, Company Secretary | 35 | 2025 |
| #4 | Sumit Babubhai Goyani | Whole Time Director | 34 | 2021 |
Financial Performance
Values in ₹ Crores| Key Metric | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | Trend |
|---|---|---|---|---|---|---|
| Total Revenue | 40.44 | 23.24 | 27.52 | 58.27 | 75.29 | Growth |
| Profit After Tax (PAT) | 1.48 | 1.69 | 4.55 | 7.20 | 13.03 | Growth |
| Operating Margin (%) | 5.34% | 14.07% | 18.28% | 15.26% | 17.94% | Up |
| Total Assets | 5.78 | 13.26 | 23.43 | 40.01 | 95.22 | - |
| Net Worth | 1.93 | 5.87 | 16.61 | 30.62 | 71.19 | - |
| Borrowings (Debt) | 1.18 | 3.64 | 2.86 | 5.05 | 6.64 | - |
| Debt to Equity Ratio | 0.61 | 0.62 | 0.17 | 0.16 | 0.09 | - |
IPO Valuation
IPO Lot Size Details
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Minimum) | 1 Lot | 1 Shares | ₹124.00 |
| Retail (Maximum) | 1612 Lots | 1612 Shares | ₹199,888.00 |
| Small HNI (sNII - Min) | 1613 Lots | 1613 Shares | ₹200,012.00 |
| Small HNI (sNII - Max) | 8064 Lots | 8064 Shares | ₹999,936.00 |
| Big HNI (bNII - Min) | 8065 Lots | 8065 Shares | ₹1,000,060.00 |
Peer Companies Comparison
| Company | CMP (₹) | P/E Ratio | P/B Ratio | Market Cap |
|---|---|---|---|---|
| Speciality Medicines (This IPO) | ₹124.00 | 12.67 | 2.32 | ₹165 Cr. |
| Sun Pharmaceutical Industries | ₹1,913.00 | 37.20 | 5.36 | ₹458,982 Cr. |
| Divi's Laboratories | ₹6,850.80 | 68.25 | 10.69 | ₹181,894 Cr. |
| Torrent Pharmaceuticals | ₹4,826.00 | 68.93 | 18.21 | ₹163,427 Cr. |
| Cipla | ₹1,471.25 | 27.85 | 3.36 | ₹118,854 Cr. |
| Zydus Lifesciences | ₹1,148.90 | 21.17 | 4.13 | ₹115,606 Cr. |
